Last reviewed · How we verify

ENJUVIA (ESTROGENS, CONJUGATED SYNTHETIC B)

DURAMED · FDA-approved approved Quality 4/100

ENJUVIA (generic name: ESTROGENS, CONJUGATED SYNTHETIC B) is a drug developed by DURAMED. It is currently FDA-approved.

At a glance

Generic nameESTROGENS, CONJUGATED SYNTHETIC B
SponsorDURAMED
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ENJUVIA

What is ENJUVIA?

ENJUVIA (ESTROGENS, CONJUGATED SYNTHETIC B) is a pharmaceutical drug developed by DURAMED.

Who makes ENJUVIA?

ENJUVIA is developed and marketed by DURAMED (see full DURAMED pipeline at /company/duramed).

What is the generic name of ENJUVIA?

ESTROGENS, CONJUGATED SYNTHETIC B is the generic (nonproprietary) name of ENJUVIA.

What development phase is ENJUVIA in?

ENJUVIA is FDA-approved (marketed).

What are the side effects of ENJUVIA?

Common side effects of ENJUVIA include Headache, Pain, Abdominal Pain, Accidental Injury, Flu Syndrome, Flatulence. Serious adverse events: Breast Cancer, Endometrial Cancer, Ovarian Cancer, Pulmonary Embolism.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing